RT Journal Article
SR Electronic
T1 Evidence for antibody as a protective correlate for COVID-19 vaccines
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.03.17.20200246
DO 10.1101/2021.03.17.20200246
A1 Kristen A. Earle
A1 Donna M. Ambrosino
A1 Andrew Fiore-Gartland
A1 David Goldblatt
A1 Peter B. Gilbert
A1 George R. Siber
A1 Peter Dull
A1 Stanley A. Plotkin
YR 2021
UL http://medrxiv.org/content/early/2021/03/20/2021.03.17.20200246.abstract
AB Though eleven novel COVID-19 vaccines have demonstrated efficacy, additional affordable, scalable, and deliverable vaccines are needed to meet unprecedented global demand. With placebo-controlled efficacy trials becoming infeasible due to the roll out of licensed vaccines, a correlate of protection is urgently needed to provide a path for regulatory approval of novel vaccines. To assess whether antibody titers may reasonably predict efficacy, we evaluated the relationship between efficacy and in vitro neutralizing and binding antibodies of 7 vaccines for which sufficient data have been generated. Once calibrated to titers of human convalescent sera reported in each study, a robust correlation was seen between neutralizing titer and efficacy (ρ= 0.79) and binding antibody titer and efficacy (ρ = 0.93), despite geographically diverse study populations subject to different forces of infection and circulating variants, and use of different endpoints, assays, convalescent sera panels and manufacturing platforms. This correlation is strengthened by substituting post-hoc analyses for efficacy against the ancestral strain (D614G), where available. Together with an accumulating body of evidence from natural history studies and animal models, these results support the use of post-immunization antibody titers as the basis for establishing a correlate of protection for COVID-19 vaccines.Competing Interest StatementDr. Plotkin consults for Janssen and Moderna; Dr. Siber reports personal fees from Clover, other from COVAXX, personal fees from CanSino, personal fees from CureVac, personal fees from Valneva, personal fees and other from Affinivax, outside the submitted work; Dr. Gilbert reports grants and non-financial support from SanofiPasteur, outside the submitted work; Dr. Ambrosino reports personal fees from Covaxx, personal fees from Clover Biopharmaceuticals, outside the submitted work.Clinical TrialN/AFunding StatementThe authors received no financial support for the research or authorship of this article.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData sharing is not applicable to this article as no new data were created or analyzed in this study. All clinical data included in the analysis are in the public domain.